Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery
Breast Cancer Research and Treatment · 2026-06 · 217 (2)
DOI: 10.1007/s10549-026-07976-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 14.05.2026. Verfasst von Sakiko Kondo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Mastectomy, Segmental, BRCA1 Protein, Breast Neoplasms. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The risk of ipsilateral breast tumor recurrence (IBTR) and the prognostic outcomes of breast-conserving surgery (BCS) for germline BRCA1/2 pathogenic variant carriers (BRCA+) remain controversial. This study aimed to investigate the differences in the incidence of IBTR and prognosis between BRCA + and noncarriers (BRCA-) after BCS. METHODS: A retrospective chart review was performed in patients with stage 0-III breast cancer who underwent genetic testing for germline BRCA1/2 and BCS between 1996 and 2020. We compared the incidence of IBTR and the characteristics and prognostic outcomes of IBTR, including overall survival (OS), breast cancer-specific survival (BCSS), and distant recurrence-free survival (DRFS), between BRCA + and BRCA- after BCS. RESULTS: We analyzed 551 patients (587 breasts with cancer), including 61 carriers (64 breasts with cancer). During the median follow-up period of 5.3 years, the 5-year IBTR rates were 3.6% in the BRCA+ group and 5.1% in the BRCA- group, and the 10-year IBTR rates were 9.5% and 8.8%, respectively (p = 0.489). The median times to IBTR were 10.2 years in BRCA + and 3.5 years in BRCA-. The discordance rate of cancer subtypes between IBTR and primary cancer was significantly higher in BRCA+ than in BRCA- (p = 0.012). No significant differences were observed in the OS, BCSS, or DRFS between the two cohorts. CONCLUSION: No significant differences were observed in the IBTR risk or prognostic outcomes between BRCA + and BRCA- after BCS. However, the longer time to IBTR and the clinicopathological features potentially consistent with new primary cancers in BRCA+ suggest the importance of shared decision-making regarding BCS and long-term intensive breast surveillance after BCS in BRCA+.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan. kidakumi@luke.ac.jp.
- Center for Medical Genetics, St. Luke's International Hospital, Tokyo, Japan. kidakumi@luke.ac.jp.
- Center for Medical Genetics, St. Luke's International Hospital, Tokyo, Japan.
- Department of Pathology, St. Luke's International Hospital, Tokyo, Japan.
- Division of Integrated Women's Health, St. Luke's International Hospital, Tokyo, Japan.
Zitieren
APA
Kondo, S., Kida, K., Suzuki, M., Kajiura, Y., Takei, J., Kanomata, N., Yamanaka, M., & Yoshida, A. (2026). Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery. Breast Cancer Research and Treatment, 217(2). https://doi.org/10.1007/s10549-026-07976-8
Vancouver
Kondo S, Kida K, Suzuki M, Kajiura Y, Takei J, Kanomata N, et al. Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery. Breast Cancer Research and Treatment. 2026;217(2). doi:10.1007/s10549-026-07976-8
BibTeX
@article{Kondo2026,
author = {Kondo, Sakiko and Kida, Kumiko and Suzuki, Misato and Kajiura, Yuka and Takei, Junko and Kanomata, Naoki and Yamanaka, Michiko and Yoshida, Atsushi},
title = {Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery},
journal = {Breast Cancer Research and Treatment},
year = {2026},
volume = {217},
number = {2},
doi = {10.1007/s10549-026-07976-8}
}
EUVIMED